Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Med Hypotheses
Prif Awduron: Kavanagh, Oisín, Marie Healy, Anne, Dayton, Francis, Robinson, Shane, O'Reilly, Niall J., Mahoney, Brian, Arthur, Aisling, Walker, Gavin, Farragher, John P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier Ltd. 2020
Pynciau:
Letter to Editors
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://ncbi.nlm.nih.gov/pubmed/33017904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mehy.2020.110110
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg